Stockscreener 앱 받기
8.35
1.21%
0.10
전일 마감가:
$8.25
열려 있는:
$8.41
하루 거래량:
22,654
Relative Volume:
0.48
시가총액:
$49.96M
수익:
$43.77M
순이익/손실:
$-35.04M
주가수익비율:
-2.5676
EPS:
-3.2521
순현금흐름:
$-5.51M
1주 성능:
+2.08%
1개월 성능:
+0.48%
6개월 성능:
-20.49%
1년 성능:
-32.52%
1일 변동 폭
$8.285
$8.5599
1주일 범위
$7.97
$8.6659
52주 변동 폭
$6.4652
$16.10
Xilio Therapeutics Inc Stock (XLO) Company Profile
명칭
Xilio Therapeutics Inc
전화
617-833-1027
주소
828 WINTER STREET, WALTHAM
Compare XLO vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
8.35 | 49.36M | 43.77M | -35.04M | -5.51M | -3.2521 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-06 | 개시 | Leerink Partners | Outperform |
| 2022-12-21 | 개시 | Chardan Capital Markets | Buy |
| 2022-01-10 | 개시 | H.C. Wainwright | Buy |
| 2021-11-16 | 개시 | Cowen | Outperform |
| 2021-11-16 | 개시 | Guggenheim | Buy |
| 2021-11-16 | 개시 | Morgan Stanley | Overweight |
| 2021-11-16 | 개시 | Raymond James | Outperform |
모두보기
Xilio Therapeutics Inc 주식(XLO)의 최신 뉴스
XLO Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts SharesCommunity Buy Signals - Newser
Is Xilio Therapeutics (XLO) Still a Buy After +2.89% Rally? 2026-05-21Wyckoff Upthrust - Newser
Xilio Therapeutics (XLO) Crushes Q1 2026 Estimates — EPS $-0.58 Tops ViewsHigh Interest Stocks - Newser
Cancer Stocks That Are Advancing the Future of Oncology Care - TradingView
Xilio Therapeutics, Inc. (XLO) reports Q1 loss, beats revenue estimates - MSN
Xilio Therapeutics (XLO) Stock Analysis: Falls -5.11%, Watching $7.94 2026-05-17Technical Analysis - Newser
Xilio Therapeutics (XLO) upgraded to buy: What does it mean for the stock? - MSN
OrbiMed group discloses stakes in Xilio Therapeutics (NASDAQ: XLO), up to 9.99% - Stock Titan
Bain Capital entities report 9.99% stake in Xilio Therapeutics (XLO) - Stock Titan
Point72 (XLO) files 13G/A showing 0% stake in Xilio Therapeutics - Stock Titan
Sirenia and Alex Silverstein report 9.9% stake in Xilio (NASDAQ: XLO) - Stock Titan
TradingKey - TradingKey
Xilio Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Xilio Therapeutics, Inc. 2026 Q1 Quarterly Report: Financials, Risk Factors, and Business Overview - Minichart
XLO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Sagimet Biosciences Releases Q1 2026 Financial Results - AlphaStreet
Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Xilio Therapeutics Reports Q1 2026 Financial Results, Advances Pipeline with XTX501 IND Filing and AbbVie Milestone Extension - Minichart
Xilio Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
According to documents submitted to the U.S. Securities and Exchange Commission (SEC), biotechnology company Xilio Therapeutics Inc. has entered into a common stock sales agreement with investment bank Leerink Partners LLC. - Bitget
Xilio Therapeutics (NASDAQ: XLO) files $250M shelf, includes $17.22M ATM - Stock Titan
Xilio Therapeutics, Inc. 1Q 2026: Revenue $12.6M, EPS $(0.58) — 10-Q Summary - TradingView
Xilio Therapeutics (XLO) boosts Q1 2026 collaboration revenue and extends cash runway into 2028 - Stock Titan
Xilio Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Xilio (Nasdaq: XLO) Q1 2026 loss narrows as cash runway extends to 2028 - Stock Titan
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and ... - Caledonian Record
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates - GlobeNewswire
XLO (Xilio Therapeutics) swings to profit, crushing estimates by 147.7 percent as stock gains.Expert Momentum Signals - newser.com
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 7, 2026 - marketscreener.com
Number of shareholders of Xilio Therapeutics, Inc. – NASDAQ:XLO - TradingView
XLO Xilio Therapeutics smashes Q4 earnings with 147.7% beat, 589.9% revenue surge, yet shares fall 1.14%.Expert Entry Points - newser.com
Xilio Therapeutics Grants Options for 146,800 Shares to New Employees - geneonline.com
New Xilio hire gets stock options for 1,982 shares at $8.32 - Stock Titan
Actuate Therapeutics Adds Oncology Expert to Board Leadership - TipRanks
Actuate Therapeutics appoints Martin Huber to board By Investing.com - Investing.com Australia
Xilio Therapeutics Inc expected to post a loss of 66 cents a shareEarnings Preview - TradingView
Net current asset value per share of Xilio Therapeutics, Inc. – NASDAQ:XLO - TradingView
XLO Q1'26 Earnings: revenue estimate is 8.52M USD - TradingView
Xilio Therapeutics (XLO) price target decreased by 28.57% to 20.40 - MSN
[ARS] Xilio Therapeutics, Inc. SEC Filing - Stock Titan
Xilio Therapeutics | ARS: Annual Report to Security Holders - Moomoo
Stock plan change and virtual 2026 annual meeting at Xilio (XLO) - Stock Titan
What failed trades Xilio Therapeutics (XLO)? (Slight Gain) 2026-04-27Market Expert Watchlist - Newser
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split - WFXG
Xilio Therapeutics | 8-K: Current report - Moomoo
Xilio Therapeutics (XLO) Stock: Growth Outlook (+2.63%) 2026-04-18Sector Analysis - Xã Vĩnh Công
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2 - Sahm
XLO: Xilio Therapeutics Presents Promising Preclinical Findings for XTX601 at AACR - GuruFocus
Xilio announces new preclinical data for XTX601 at AACR - TipRanks
Xilio Therapeutics appoints Cheryl Blanchard to board By Investing.com - Investing.com India
Xilio Therapeutics Inc (XLO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):